<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Dogwood Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc</link>
<description>Latest news and press releases for Dogwood Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/dogwood-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835605f78dffbe2df0edfb3.webp</url>
<title>Dogwood Therapeutics, Inc.</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc</link>
</image>
<item>
<title>Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-announces-worldwide-development-and-commercialization-partnership-for-anti-viral-assets-with-potential-value-up-to-dollar100m</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-announces-worldwide-development-and-commercialization-partnership-for-anti-viral-assets-with-potential-value-up-to-dollar100m</guid>
<pubDate>Thu, 23 Apr 2026 13:00:00 GMT</pubDate>
<description>- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royalty up to 15% on Net Sales - - Dogwood Entitled to a Percentage of Future Development and Regulatory Milestones, as well as 9% of Future Capital Raised by PRIDCor to Advance Development of IMC-1 and IMC-2 - ALPHARETTA, Ga., April 23, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX)</description>
</item>
<item>
<title>Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-announces-fda-acceptance-of-sp16-investigational-new-drug-application-for-the-treatment-of-chemotherapy-induced-pain-and-neuropathy</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-announces-fda-acceptance-of-sp16-investigational-new-drug-application-for-the-treatment-of-chemotherapy-induced-pain-and-neuropathy</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National</description>
</item>
<item>
<title>Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing</description>
</item>
<item>
<title>CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/ck-life-sciences-establishes-sequencio-therapeutics-to-advance-therapeutic-cancer-vaccines-development</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/ck-life-sciences-establishes-sequencio-therapeutics-to-advance-therapeutic-cancer-vaccines-development</guid>
<pubDate>Tue, 10 Mar 2026 12:21:00 GMT</pubDate>
<description>HONG KONG, HK / ACCESS Newswire / March 10, 2026 / CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences" or the "Company", Stock Code: 0775) today announced the establishment of Sequencio Therapeutics ("Sequencio"), a wholly-owned subsidiary ...</description>
</item>
<item>
<title>Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-announces-50-enrollment-133000057</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-announces-50-enrollment-133000057</guid>
<pubDate>Mon, 02 Feb 2026 13:30:00 GMT</pubDate>
<description>- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain (“HALT-CINP”) trial.</description>
</item>
<item>
<title>Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-inc-announces-financing-133000753</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-inc-announces-financing-133000753</guid>
<pubDate>Mon, 12 Jan 2026 13:30:00 GMT</pubDate>
<description>Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for up to approximately $12.5</description>
</item>
<item>
<title>Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-announces-positive-interim-151500668</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-announces-positive-interim-151500668</guid>
<pubDate>Mon, 22 Dec 2025 15:15:00 GMT</pubDate>
<description>- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below rates typically observed with other FDA approved chronic pain medicines - ATLANTA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announces positive re</description>
</item>
<item>
<title>Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-files-synthetic-halneuron-130000818</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-files-synthetic-halneuron-130000818</guid>
<pubDate>Tue, 02 Dec 2025 13:00:00 GMT</pubDate>
<description>- New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron®- - New Synthetic Process to be Used for Phase 3 Development Provides Higher Manufacturing Yields and Reduces ...</description>
</item>
<item>
<title>Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-announces-enrollment-first-100-134500767</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-announces-enrollment-first-100-134500767</guid>
<pubDate>Tue, 11 Nov 2025 13:45:00 GMT</pubDate>
<description>- Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well tolerated ATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the ...</description>
</item>
<item>
<title>Dogwood Therapeutics Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-reports-third-quarter-134500315</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-reports-third-quarter-134500315</guid>
<pubDate>Thu, 06 Nov 2025 13:45:00 GMT</pubDate>
<description>- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured exclusive worldwide, royalty free license to develop and commercialize SP16 as a synergistic and complementary pipeline treatment for cancer-related pain in an all-stock transaction - ATLANTA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-sta</description>
</item>
<item>
<title>Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-report-third-quarter-131500873</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-report-third-quarter-131500873</guid>
<pubDate>Thu, 30 Oct 2025 13:15:00 GMT</pubDate>
<description>ATLANTA, GA / ACCESS Newswire / October 30, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development‐stage biotechnology company developing new medicines to treat pain and neuropathy, announced today that it will report third ...</description>
</item>
<item>
<title>Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-participate-maxim-growth-124500313</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-participate-maxim-growth-124500313</guid>
<pubDate>Tue, 14 Oct 2025 12:45:00 GMT</pubDate>
<description>ATLANTA, GA / ACCESS Newswire / October 14, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathic disorders, today announces that Greg Duncan, ...</description>
</item>
<item>
<title>DWTX: Licenses SP16 for Treatment of Cancer Related Pain…</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dwtx-licenses-sp16-for-treatment-of-cancer-related-pain</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dwtx-licenses-sp16-for-treatment-of-cancer-related-pain</guid>
<pubDate>Fri, 10 Oct 2025 12:04:00 GMT</pubDate>
<description>By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Business Update All-Stock Licensing Deal for Treatment of Cancer Related Pain On September 29, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a royalty-free, global license deal with Serpin Pharma for SP16 for the management of cancer related pain (CRP), including a broad range of chemotherapy induced neuropathy</description>
</item>
<item>
<title>Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-inc-chief-medical-124500535</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-inc-chief-medical-124500535</guid>
<pubDate>Tue, 07 Oct 2025 12:45:00 GMT</pubDate>
<description>ATLANTA, GEORGIA / ACCESS Newswire / October 7, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain, today announced that its Chief Medical Officer will ...</description>
</item>
<item>
<title>Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-secures-exclusive-worldwide-111500183</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-secures-exclusive-worldwide-111500183</guid>
<pubDate>Mon, 29 Sep 2025 11:15:00 GMT</pubDate>
<description>-A first-in-class LRP1 agonist, SP16 phase 1b Chemotherapy Induced Neuropathy (CIPN) Study fully funded by the National Cancer Institute, with projected patient enrollment beginning in the first half of 2026- -SP16 has demonstrated both anti-inflammatory and neural repair activity that has the potential to treat CIPN, synergistically complementing Halneuron®, the Company’s late stage NaV1.7 inhibitor, which has demonstrated significant pain reduction in previous Phase 2 studies- -Webcast today,</description>
</item>
<item>
<title>Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-participate-fireside-chat-131500906</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-participate-fireside-chat-131500906</guid>
<pubDate>Wed, 03 Sep 2025 13:15:00 GMT</pubDate>
<description>ATLANTA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announces it will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel. Greg Duncan, Chief Executive Officer will participate in a fireside chat with Sean Lee, VP of</description>
</item>
<item>
<title>Dogwood Therapeutics Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-reports-second-quarter-130000976</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-reports-second-quarter-130000976</guid>
<pubDate>Wed, 13 Aug 2025 13:00:00 GMT</pubDate>
<description>- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track for Q4 2025 - - Low discontinuation rate (5.8%) due to adverse events in the first 38 patients completing the trial suggests Halneuron® and placebo treatment have been generally well tolerated - - Cash on hand of $13.4 million provides operational runway through Q1 2026 - ATLANTA, Aug. 13, 2025 (GLOBE NEWSW</description>
</item>
<item>
<title>Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-announces-enrollment-first-170800158</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-announces-enrollment-first-170800158</guid>
<pubDate>Thu, 07 Aug 2025 17:08:00 GMT</pubDate>
<description>- Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 - - Low discontinuation rate (6%) due to adverse events amongst the first 35 patients completing the trial suggests Halneuron® and placebo treatment have been generally well tolerated - ATLANTA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to trea</description>
</item>
<item>
<title>Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-report-second-quarter-131500336</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-report-second-quarter-131500336</guid>
<pubDate>Wed, 06 Aug 2025 13:15:00 GMT</pubDate>
<description>ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development‐stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, announced today that it will report second quarter 2025 financial results on Wednesday, August 13, 2025 before the open of the financial markets. About Dogwood Therapeutics Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new me</description>
</item>
<item>
<title>Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference</title>
<link>https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-present-sidoti-small-131500729</link>
<guid isPermaLink="true">https://6ix.com/company/dogwood-therapeutics-inc/news/dogwood-therapeutics-present-sidoti-small-131500729</guid>
<pubDate>Tue, 03 Jun 2025 13:15:00 GMT</pubDate>
<description>ATLANTA, June 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced that CEO, Greg Duncan, will present a corporate overview at the Sidoti Small-Cap Virtual Conference being held on Wednesday, June 11, 2025 – Thursday, June 12, 2025. Presentation Date: Wednesday, June 11, 2025 Time: 9:15am Easter Time (Track 1) Webcast Link</description>
</item>
</channel>
</rss>